You are here

Award Data

For best search results, use the search terms first and then apply the filters
Reset

The Award database is continually updated throughout the year. As a result, data for FY24 is not expected to be complete until March, 2025.

Download all SBIR.gov award data either with award abstracts (290MB) or without award abstracts (65MB). A data dictionary and additional information is located on the Data Resource Page. Files are refreshed monthly.

The SBIR.gov award data files now contain the required fields to calculate award timeliness for individual awards or for an agency or branch. Additional information on calculating award timeliness is available on the Data Resource Page.

  1. T SS needle protein inhibitors for the treatment of P aeruginosa infection

    SBC: MICROBIOTIX, INC.            Topic: NIAID

    DESCRIPTION provided by applicant The inability to treat many Gram negative bacterial infections effectively with existing antibiotics is a major medical crisis Pseudomonas aeruginosa is a prime example of clinical isolates from critically ill patients are resistant to three or more drugs The overall goal of this project is to address the critical medical need by a novel approach of iden ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  2. Optimization of small molecule triazine antituberculars for in vivo efficacy

    SBC: COLLABORATIONS PHARMACEUTICALS INC            Topic: NIAID

    DESCRIPTION provided by applicant Tuberculosis TB is due to infection with the pathogen Mycobacterium tuberculosis Mtb This disease represents a global health pandemic as based on WHO statistics it claims the lives of approximately million people per year while infecting nearly million New drugs are urgently needed with novel mechanisms of action that treat this disease while also ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  3. Antibody targeting of ADAM for treatment of triple negative breast cancer

    SBC: ADECTO PHARMACEUTICALS, INC.            Topic: NCI

    DESCRIPTION provided by applicant Triple negative breast cancers TNBCs account for of breast cancer deaths and lack targeted therapies Drs Sonenshein Mineva and Romagnoli and their co workers recently identified the non essential cell surface protein ADAM A Disintegrin and Metalloprotease as a pivotal promoter of breast tumor growth and metastasis and validated it as a target o ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  4. Novel immunotherapy strategy for treatment of pancreatic cancer

    SBC: Oncotab, Inc.            Topic: NCI

    DESCRIPTION provided by applicant Pancreatic cancer has the worst prognosis of all cancers and is the fourth leading cause of cancer related deaths in the United States Patients usually present with advanced disease making curative attempts difficult Surgery is the only curative therapy since radiotherapy and chemotherapy remain largely ineffective coupled with undesirable side effects Desp ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  5. High Fidelity Computational Models for Aggregated Tissue Interaction in Surgical Simulations

    SBC: CFD RESEARCH CORPORATION            Topic: DHP16A001

    Surgical simulations aiming to support surgeon practices and medical education have attracted enormous research effort over the last two decades. However, the physical reality, especially on simulating aggregated tissue interaction, is still unsatisfactory. In this proposed work, an open source surgery simulation framework, SoFMIS, will be utilized and enhanced with tissue interaction models to a ...

    STTR Phase I 2016 Department of DefenseDefense Health Agency
  6. Bio-mathematical Models of Aggregated Tissues & Organ Properties

    SBC: Corvid Innovation LLC            Topic: DHP16A001

    Realistic surgical simulation requires a combination of representative tissue geometry, accurate tissue material properties and lifelike tool-tissue interaction forces. Recent advances in computational power and imaging modalities have provided the capability to represent the anatomical details required for surgical training; however, the mathematical models which govern the underlying tissue pro ...

    STTR Phase I 2016 Department of DefenseDefense Health Agency
  7. Bio-Mathematical Models of Aggregated Tissues & Organ Properties

    SBC: BIOMOJO LLC            Topic: DHP16A001

    BioMojo LLC and the Departments of Mathematics and Biomedical Engineering at the University of North Carolina Chapel Hill, will develop a preliminary bio mathematical model framework to represent how human tissues interact and behave at their boundaries. Tissue interaction properties (e.g. tensile, shear, friction, and so forth) of connective, epithelial, muscular, and nervous tissue including su ...

    STTR Phase I 2016 Department of DefenseDefense Health Agency
  8. Mobile Phone Intervention for Physical Activity Maintenance in African American Men (MobileMen)

    SBC: KLEIN BUENDEL, INC.            Topic: NIMHD

    DESCRIPTION provided by applicant African American men experience health disparities across a number of preventable chronic diseases including cardiovascular disease strokes obesity and diabetes Physical activity PA is a modifiable risk factor for these conditions The few PA promotion studies that have included African American men have resulted in successful short term behavior change ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  9. CellRaft Array for Screening and Isolation of Highly Effective Cytotoxic T Cells

    SBC: CELL MICROSYSTEMS INC            Topic: NIAID

    PROJECT SUMMARY Cell Microsystems Inc is an early stage biotechnology company whose mission is the commercialization of a novel cost effective platform enabling the identification and efficient isolation of viable cells based on morphologic and fluorescence signatures as well as characteristics that change over time The CellRaft technology is based on a unique cell array recently developed ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
  10. Therapy for drug resistant influenza strains by nucleic acid targeting of respiratory airways

    SBC: Abcombi Biosciences Inc            Topic: NIAID

    PROJECT SUMMARY Antiviral drugs are a crucial countermeasure for influenza A virus IAV particularly in circumstances of increased IAV incidence or if a vaccine is unavailable e g virulent H N IAV However the emergence of IAV strains that are resistant to current antivirals H N underscores the need for new treatment strategies particularly those that modify the host response IAVs ...

    STTR Phase I 2016 Department of Health and Human ServicesNational Institutes of Health
US Flag An Official Website of the United States Government